UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002317
Receipt number R000002300
Scientific Title A phase III randomised trial of lobectomy versus limited resection (segmentectomy) for small (2 cm or less) peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)
Date of disclosure of the study information 2009/08/10
Last modified on 2020/02/04 19:12:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase III randomised trial of lobectomy versus limited resection (segmentectomy) for small (2 cm or less) peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)

Acronym

A phase III randomised trial of lobectomy versus limited resection (segmentectomy) for small (2 cm or less) peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)

Scientific Title

A phase III randomised trial of lobectomy versus limited resection (segmentectomy) for small (2 cm or less) peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)

Scientific Title:Acronym

A phase III randomised trial of lobectomy versus limited resection (segmentectomy) for small (2 cm or less) peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)

Region

Japan


Condition

Condition

small (2 cm or less) peripheral non-small cell lung cancer

Classification by specialty

Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the non-inferiority of overall survival of segmentectomy for lobectomy in patients with small peripheral non-small cell lung cancer (2 cm or less, the proportion of maximum diameter of the tumor itself to consolidation >0.5) .

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

overall survival

Key secondary outcomes

postoperative respiratory function, relapse-free survival, proportion of local recurrence, adverse events, proportion of completion of segmentectomy, days of hospitalization, duration of chest tube placement, operation time, blood loss, number of used auto-sutures.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

A: Pulmonary lobectomy

Interventions/Control_2

B: Pulmonary segmentectomy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

Preoperative criteria,
1) Contrast-enhanced thoracic CT fulfills all of the following conditions:
i) single tumor,
ii) non-small cell lung cancer is suspected,
iii) Center of tumor is located in the outer third of the lung field,
iv) the tumor is not located at middle lobe,
v) no lymph node metastasis.
2) Thin-section CT fulfills both of the following conditions:
i) maximum diameter of the tumor is 2 cm or less,
ii) the proportion of maximum diameter of the tumor itself to consolidation is more than 0.5. 3) Aged 20 to 79 years old.
4) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed).
5) No prior chemotherapy or radiation therapy for any malignant diseases.
6) Expected postoperative FEV1.0>=800 mL and PaO2>=65 torr.
7) Performance status of 0 or 1.
8) Sufficient organ functions.
9) preoperative body temperature is 38C or less
10)Written informed consent.

Intraoperative criteria,
1) the date of surgery (second registration) is within 28 days of the first registration,
2) histologically confirmed either adenocarcinoma, adenosquamous carcinoma,
large cell carcinoma, or non-small cell lung cancer (detailed category unknown),
3) neither malignant pleural effusion nor pleural dissemination,
4) no lymph node metastasis
5) technically possible to perform any of the following procedures: lobectomy, segmentectomy,
and nodal dissection.

Key exclusion criteria

1) Active bacterial or fungous infection.
2) Simultaneous or metachronous (within the past 5 years) double cancers.
3) Women during pregnancy or breast-feeding.
4) Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema.
5) Psychosis.
6) Systemic steroids medication.
7) Uncontrollable diabetes mellitus.
8) Uncontrollable hypertension.
9) History of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.

Target sample size

1100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hisao Asamura

Organization

Keio University School of Medicine

Division name

Division of Thoracic Surgery

Zip code


Address

Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, JAPAN

TEL

03-5363-3805

Email

hasamura@a3.keio.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masahiro Tsuboi / Hisashi Saji

Organization

JCOG0802 Study Coordinating Office

Division name

Division of Thoracic Surgery, Kanagawa Cancer Center/St. Marianna University School of Medicine Hosp

Zip code


Address

1-1-2, Nakao, Asahi-ku, Yokohama, 241-0815, JAPAN / 2-16-1, Sugao, Miyamae-ku, Kawasaki, 216-8511

TEL

(045)-391-5761(044)-977-8111

Homepage URL

http://www.jcog.jp/

Email

JCOG_sir@ml.jcog.jp


Sponsor or person

Institute

Japan Clinical Oncology Group(JCOG)

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

West Japan Oncology Group (WJOG)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

旭川医科大学病院(北海道)
国立病院機構仙台医療センター(宮城県)
東北大学病院(宮城県)
山形県立中央病院(山形県)
山形大学医学部附属病院(山形県)
公立大学法人 福島県立医科大学附属病院(福島県)
茨城県立中央病院・茨城県地域がんセンター(茨城県)
栃木県立がんセンター(栃木県)
群馬県立がんセンター(群馬県)
千葉県立がんセンター(千葉県)
国立がん研究センター東病院(千葉県)
千葉大学医学部(千葉県)
国立がん研究センター中央病院(東京都)
杏林大学医学部(東京都)
東京医科大学病院(東京都)
がん・感染症センター都立駒込病院(東京都)
慶應義塾大学病院(東京都)
がん研究会有明病院(東京都)
順天堂大学医学部附属順天堂医院(東京都)
聖マリアンナ医科大学(神奈川県)
神奈川県立病院機構神奈川県立がんセンター(神奈川県)
横浜市立市民病院(神奈川県)
横浜市立大学附属市民総合医療センター(神奈川県)
神奈川県立循環器呼吸器病センター(神奈川県)
相模原協同病院(神奈川県)
北里大学病院(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
西新潟中央病院(新潟県)
金沢大学医学部(石川県)
石川県立中央病院(石川県)
昭和伊南総合病院(長野県)
信州大学医学部附属病院(長野県)
岐阜市民病院(岐阜県)
岐阜大学医学部附属病院(岐阜県)
静岡県立静岡がんセンター(静岡県)
浜松医科大学医学部附属病院(静岡県)
愛知県がんセンター中央病院(愛知県)
名古屋大学医学部(愛知県)
三重大学医学部附属病院(三重県)
京都大学医学部附属病院(京都府)
大阪大学医学部(大阪府)
大阪府立病院機構大阪府立成人病センター(大阪府)
大阪府立病院機構大阪府立呼吸器・アレルギー医療センター(大阪府)
国立病院機構近畿中央胸部疾患センター(大阪府)
大阪市立総合医療センター(大阪府)
刀根山病院(大阪府)
市立吹田市民病院(大阪府)
大阪市立大学医学部附属病院(大阪府)
兵庫県立がんセンター(兵庫県)
神戸市立医療センター中央市民病院(兵庫県)
兵庫県立淡路病院(兵庫県)
近畿大学医学部奈良病院(奈良県)
鳥取大学医学部附属病院(鳥取県)
倉敷中央病院(岡山県)
岡山大学病院(岡山県)
川崎医科大学附属病院(岡山県)
国立病院機構呉医療センター・中国がんセンター(広島県)
広島大学病院(広島県)
広島市立安佐市民病院(広島県)
広島市立広島市民病院(広島県)
済生会広島病院(広島県)
山口宇部医療センター(山口県)
山口大学医学部附属病院(山口県)
国立病院機構四国がんセンター(愛媛県)
高知医療センター(高知県)
国立病院機構九州がんセンター(福岡県)
社会医療法人 製鉄記念八幡病院(福岡県)
九州大学病院(福岡県)
長崎大学病院(長崎県)
日本赤十字社 長崎原爆病院(長崎県)
熊本大学医学部(熊本県)
熊本中央病院(熊本県)
熊本地域医療センター(熊本県)
大分大学医学部附属病院(大分県)
新別府病院(大分県)
大分県立病院(大分県)


Other administrative information

Date of disclosure of the study information

2009 Year 08 Month 10 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pubmed/31078312

Number of participants that the trial has enrolled

1319

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2009 Year 01 Month 09 Day

Date of IRB


Anticipated trial start date

2009 Year 08 Month 10 Day

Last follow-up date

2020 Year 08 Month 10 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is conducted as intergroup study of Japan Clinical Oncology Group(JCOG) and West Japan Oncology Group(WJOG) .


Management information

Registered date

2009 Year 08 Month 10 Day

Last modified on

2020 Year 02 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002300


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name